文献速递甲状腺疾病

基于甲状腺分化评分定义的BRAF突变乳头状甲状腺癌亚型特征分析

Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该研究基于癌症基因组图谱甲状腺癌研究中227例BRAF突变乳头状甲状腺癌,按甲状腺分化评分分为BRAF-TDShi与BRAF-TDSlo两亚型并比较特征。BRAF-TDSlo肿瘤占83%,更大、淋巴结受累更多、远处转移更频繁,完全缓解率低于BRAF-TDShi。RAS特征富集及靶向TGFβ-SMAD通路的microRNA过表达定义了两个临床特征和预后不同的亚型。

要点

  • BRAF-TDSlo亚型占83%,肿瘤更大、淋巴结受累更多、远处转移更频繁。
  • BRAF-TDShi组完全缓解率94% vs BRAF-TDSlo组57%(P < 0.01)。
  • BRAF-TDShi组富集RAS特征及miR-204、miR-205、miR-144过表达。

核心结论

  • RAS特征富集、细胞极性关键基因及靶向TGFβ-SMAD通路的特定microRNA定义了两个临床特征和预后不同的BRAF突变乳头状甲状腺癌亚型。

研究设计与样本

  • 研究纳入癌症基因组图谱甲状腺癌研究中227例BRAF突变乳头状甲状腺癌,按甲状腺分化评分分为BRAF-TDShi和BRAF-TDSlo两组,比较人口学、临床病理和分子特征。

主要发现

  • BRAF-TDSlo肿瘤占83%,BRAF-TDShi肿瘤占17%。
  • BRAF-TDSlo组相较于BRAF-TDShi组在黑人中更常见(6% vs 0%,P = 0.035),在西班牙裔中更常见(12% vs 0%,P = 0.05)。
  • BRAF-TDSlo组肿瘤更大(2.95 ± 1.7 vs 2.03 ± 1.5,P = 0.002),受累淋巴结更多(3.9 ± 5.8 vs 2.0 ± 4.2,P = 0.042),远处转移频率更高(3% vs 0%,P = 0.043)。
  • 基因集富集分析显示BRAF-TDShi组RAS特征正向富集,BRAF-TDSlo组相应反向变化。
  • BRAF-TDShi组中靶向TGFβ-SMAD通路节点的microRNA miR-204、miR-205和miR-144过表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The BRAFV600E mutation has been associated with more advanced clinical stage in papillary thyroid cancer (PTC) and decreased responsiveness to radioiodine (RAI). However, some BRAF mutant PTCs respond to RAI and have an indolent clinical behavior suggesting the presence of different subtypes of BRAF mutant tumors with distinct prognosis. OBJECTIVE: To characterize the molecular and clinical features of 2 subtypes of BRAF-mutant PTCs defined by their degree of expression of iodine metabolism genes. DESIGN: 227 BRAF-mutant PTCs from the Cancer Genome Atlas Thyroid Cancer study were divided into 2 subgroups based on their thyroid differentiation score (TDS): BRAF-TDShi and BRAF-TDSlo. Demographic, clinico-pathological, and molecular characteristics of the 2 subgroups were compared. RESULTS: Compared to BRAF-TDShi tumors (17%), BRAF-TDSlo tumors (83%) were more frequent in blacks and Hispanics (6% vs 0%, P = 0.035 and 12% vs 0%, P = 0.05, respectively), they were larger (2.95 ± 1.7 vs 2.03 ± 1.5, P = 0.002), with more tumor-involved lymph nodes (3.9 ± 5.8 vs 2.0 ± 4.2, P = 0.042), and a higher frequency of distant metastases (3% vs 0%, P = 0.043). Gene set enrichment analysis showed positive enrichment for RAS signatures in the BRAF-TDShi cohort, with corresponding reciprocal changes in the BRAF-TDSlo group. Several microRNAs (miRs) targeting nodes in the transforming growth factor β (TGFβ)-SMAD pathway, miR-204, miR-205, and miR-144, were overexpressed in the BRAF-TDShi group. In the subset with follow-up data, BRAF-TDShi tumors had higher complete responses to therapy (94% vs 57%, P < 0.01) than BRAF-TDSlo tumors. CONCLUSION: Enrichment for RAS signatures, key genes involved in cell polarity and specific miRs targeting the TGFβ-SMAD pathway define 2 subtypes of BRAF-mutant PTCs with distinct clinical characteristics and prognosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Boucai L, Seshan V, Williams M, et al. Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score. J Clin Endocrinol Metab. 2022. PMID: 34897468. doi:10.1210/clinem/dgab851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。